Introduction
============

Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population, especially in older people. AF is an independent risk factor for ischemic stroke,^[@b1]^ and oral anticoagulant therapy (OAT) with vitamin K antagonists (VKAs) is effective in reducing ischemic complications. Nevertheless, the rate of bleeding is significantly higher in patients receiving OAT compared to the general population and differs among clinical trials ranging from 1.3% to 7.2% per year.^[@b2]^ Intracranial (ICH) and subdural hemorrhages represent life‐threatening complications.^[@b3]--[@b4]^ Warfarin‐associated ICH is 7‐ to 10‐fold higher than spontaneous ICH and occurs in about 1% of patients on OAT.^[@b4]--[@b5]^ ICH has tremendous negative clinical impact as it is associated with about a 50% increase in risk of death.^[@b6]^

The risk for hemorrhagic stroke typically increases with INR level, nevertheless ICH may occur also in patients within the therapeutic range (TTR).^[@b7]--[@b8]^ The reason for bleeding in patients within normal TTR is still unclear.

We have recently shown that low serum values of vit E/chol, a known antioxidant, are associated with higher incidence of myocardial infarction (MI) and stroke in NVAF.^[@b9]^ However, vitamin E possesses additional anticoagulant and antiplatelet effects, which may account not only for ischemic events but also for bleeding complication; thus a relationship between vitamin E supplementation and hemorrhagic stroke has been demonstrated.^[@b10]--[@b18]^ Indeed, vitamin E inhibits activation of vitamin K‐dependent clotting factors and platelet aggregation.^[@b19]--[@b25]^ We hypothesized that vitamin E may exert an anticoagulant effect which ultimately favors bleeding complication in patients treated with warfarin or acenocumarol.

Therefore, the aim of this study was to investigate the relationship between serum vit E/chol concentration and bleeding events in NVAF patients given OAT, and the clinical variables associated with vitamin E serum levels.

Methods and Materials
=====================

Patient Selection
-----------------

In this retrospective, single‐center, observational cohort study, we identified 566 out of 1012 NVAF patients who were on OAT and followed up for at least 3 months. These patients are part of a prospective study which is still ongoing. Preliminary data from this trial have been recently published.^[@b9]^ To be included, analysis of vitamin E had to be done on each patient.

All patients were consecutively recruited from I Clinica Medica---Atherothrombosis Center of Sapienza University of Rome between November 2007 and November 2012. The Center established the date for the subsequent visits, prescribed the daily VKA dosages, and monitored and recorded changes in patients\' habits, diet, comedications, intercurrent illnesses, bleeding, and thrombotic complications.

Exclusion criteria were mechanical or biologic prosthetic valves, severe valvulopathies, severe congestive heart failure (NYHA functional class IV), congenital heart diseases, severe cognitive impairment, and chronic inflammatory diseases. Furthermore, subjects were excluded from the study if they had neoplastic diseases, liver cirrhosis, or if they were taking any antioxidant supplementation.

Written informed consent was obtained from all subjects. The study was approved by the local Ethical Committee (January 17, 2013 no. 2619) and was conducted in accordance with the principles embodied in the Declaration of Helsinki. Routine blood laboratory tests, including fasting lipid profile and 12‐lead ECG were also performed. Arterial hypertension was defined as repeatedly elevated blood pressure exceeding 140/90 mm Hg or use of antihypertensive drugs.^[@b26]^ Hypercholesterolemia, metabolic syndrome, diabetes, and heart failure were defined as previously described.^[@b27]--[@b30]^

Patients were stratified for stroke risk evaluation according to the CHADS~2~ score.^[@b31]^ The risk for bleeding was assessed using the HAS‐BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly \[≥65 years\], Drugs/alcohol concomitantly).^[@b32]^ Quality of anticoagulation was calculated as time in therapeutic range (TTR) using PARMA 5.0 software from Instrumentation Laboratory.^[@b33]^

Follow‐up
---------

Outcome events were recorded during follow‐up visits that were scheduled every 2 to 4 weeks for INR monitoring. When a patient experienced a primary outcome, follow‐up time was stopped. Patients who missed check‐ups for more than 1 month were contacted (personally or through their family or general practitioner) and the reason for interrupting treatment monitoring was recorded. Moreover, patients were contacted by phone every 3 months for general clinical evaluation. A standardized questionnaire was carried out regarding hospital admission and changes in prescribed drugs. Given that dietary changes could potentially influence anticoagulation rate by warfarin and serum vitamin E level, adherence to the Mediterranean diet was investigated by administration of a dietary questionnaire.^[@b34]^

Primary Outcome Events
----------------------

Time to the first episode of bleeding events (major or minor) was the primary outcome of the study. Bleeding events were classified according to the International Society on Thrombosis and Haemostasis (ISTH).^[@b35]^ Major bleeding was defined as fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more or leading to transfusion of 2 or more units of whole blood or red cells. All cases of clinically relevant bleeding events which were not classified as major were considered "minor".

Secondary Outcome Events
------------------------

Major adverse cardiovascular events (MACEs) were considered the secondary outcome of the study. MACEs included : transient ischemic attack (TIA), defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction; ischemic stroke, defined as cerebral infarction; nonfatal acute MI according to ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction;^[@b36]^ or cardiovascular death, defined as death associated with TIA/Stroke, MI, significant arrhythmia, congestive heart failure, or other underlying severe vascular disease.

Death was classified as cardiovascular unless an unequivocal noncardiovascular cause of death was confirmed by the central adjudication committee.

Events Validation
-----------------

Bleedings and MACEs were assessed by clinical documentation (clinical and instrumental reports, letter of hospital discharge) or ambulatory screening. Events were certified by an internal independent committee blinded from vitamin E levels (FV).

Blood Collection and Laboratory Analysis
----------------------------------------

After overnight fasting and supine rest for at least 10 minutes, blood was withdrawn from the antecubital vein. Serum was divided into aliquots and stored at −80°C.

Vitamin E
---------

Serum levels of vitamin E (α‐tocopherol) were measured by high‐performance liquid chromatography (HPLC) as previously reported.^[@b37]^ Levels were expressed as ratio (μmol/mmol) between serum α‐tocopherol concentration (μmol/L) and serum total cholesterol concentration (mmol/L) (vit E/chol), which better express the circulating (absolute) levels of vitamin E.^[@b38]^

Statistical Analysis
--------------------

Categorical variables were reported as counts (percentage) and continuous variables as means±standard deviation (SD) unless otherwise indicated. Independence of categorical variables was tested by χ^2^ test. Normal distribution of parameters was assessed by Kolmogorov--Smirnov test.

Student unpaired *t* test and Pearson product‐moment correlation analysis were used for normally distributed continuous variables. Appropriate nonparametric tests (Mann--Whitney U test and Spearman rank correlation test) were employed for all the other variables.

After dividing the AF population into quartiles according to vit E/chol serum levels, the cumulative risk of bleeding within each quartile was estimated through the Kaplan--Meier method. The survival curves of the 4 groups were then formally compared using the log‐rank test.

As follow‐up time was different among patients, Cox proportional hazards regression analysis was used to calculate the adjusted relative hazards of outcome events by each clinical variable.

At baseline, in addition to vit E/chol serum levels, potential predictors of bleeding events were considered: age, gender, hypertension, history of MI, history of stroke, heart failure, diabetes, TTR, treatment with ACE‐inhibitors/ARBs, β‐blockers, antiplatelet, and statins.

Of the above reported variables, only those with values of *P*\<0.05 in the univariate analysis were candidates for the multivariable model that was finally determined in a forward stepwise variable selection procedure. Only *P*\<0.05 were considered as statistically significant.

In order to analyze the role of vitamin E on minor bleedings, time to minor events was analyzed estimating the competing risk model of Fine and Gray, where the competing event was a major event. Results are expressed as subdistributional hazard ratio (sHR).

To check the assumption of proportional hazards, a Grambsch and Therneau test was performed.

The sample size was planned using a log‐rank test for comparing the first and fourth quartile. We planned a power of 90% and a type‐I error rate of 5%, and an HR of 2 for comparing the first and fourth quartile. As a consequence, a total of 30 events in the first and last quartile combined were planned in order to guarantee the prescribed power.

All tests were 2‐tailed and analyses were performed using computer software packages (SPSS‐13.0, SPSS Inc.).

Results
=======

Clinical Variables Affecting Vitamin E Serum Levels
---------------------------------------------------

Clinical characteristics of NVAF population are reported in [Table 1](#tbl01){ref-type="table"}. In the overall population vitamin E serum levels were 4.61±1.99 μmol/mmol cholesterol.

###### 

Baseline Characteristics

  ----------------------------- -----------
  Patients, n                   566
  Age, y                        73.4±8.2
  Gender, males                 335 (59%)
  BMI, kg/m^2^                  27.3±4.4
  Arterial hypertension         467 (82%)
  Diabetes                      105 (19%)
  History of stroke/TIA         82 (14%)
  History of MI/CHD             116 (20%)
  Anti‐platelet therapy         83 (15%)
  ACE‐inhibitors/ARBs           385 (68%)
  Statins                       240 (42%)
  β‐blockers                    205 (36%)
  Ca‐antagonists                182 (32%)
  TTR, %                        64.0±16.7
  CHADS~2~ score                1.96±1.2
  HAS‐BLED score                1.50±0.80
  Mediterranean dietary score   5.22±1.59
  ----------------------------- -----------

ACE indicates angiotensin‐converting enzyme; ARBs, angiotensin receptor blockers; BMI, body mass index; CHADS2, congestive heart failure, hypertention, age\>75, diabetes mellitus, and prior stroke or TIA; HAS‐BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (≥65 years), Drugs/alcohol concomitantly; MI, myocardial infarction; TIA, transient ischemic attack; TTR, therapeutic INR range.

Cardiovascular risk factors and therapies which could potentially affect vitamin E serum levels were analyzed ([Table 2](#tbl02){ref-type="table"}).

###### 

Factors Affecting Vitamin E Serum Levels

  Variable                                                                    β        95% CI   *P* Value   
  --------------------------------------------------------------------------- -------- -------- ----------- -------
  Age, y                                                                      −0.013   −0.023   0.017       0.764
  Gender, males                                                               −0.030   −0.456   0.213       0.477
  BMI, kg/m^2^                                                                0.009    −0.035   0.043       0.832
  Arterial hypertension                                                       −0.064   −0.911   0.130       0.141
  Diabetes                                                                    −0.065   −0.752   0.105       0.139
  History of stroke/TIA                                                       0.024    −0.338   0.608       0.575
  History of MI/CHD                                                           −0.005   −0.439   0.89        0.906
  Antiplatelet therapy                                                        −0.020   −0.588   0.363       0.641
  ACE‐inhibitors/ARBs                                                         −0.074   −0.732   0.052       0.089
  Statins                                                                     −0.055   −0.565   0.122       0.205
  β‐blockers                                                                  0.042    −0.184   0.527       0.343
  Ca‐antagonists                                                              −0.010   −0.395   0.314       0.823
  Mediterranean dietary score                                                 0.109    0.021    0.254       0.021
  Olive oil, ≥1 spoon/day                                                     0.097    0.028    1.24        0.040
  Fruit, ≥1 serving/day                                                       0.058    −0.214   0.944       0.216
  Vegetables or salad, ≥1 serving/day                                         0.010    −0.636   0.450       0.834
  Fruit and vegetables, ≥1 serving/day                                        0.026    −0.287   0.512       0.580
  Legumes, ≥2 servings/week                                                   0.059    −0.136   0.623       0.209
  Fish, ≥3 servings/week                                                      0.052    −0.212   0.759       0.269
  Wine, ≥1 glass/day                                                          0.088    −0.016   0.747       0.061
  Meat, \<1 serving/day                                                       −0.035   −0.550   0.247       0.456
  White bread (\<1/day) and rice (\<1/week) or whole‐grain bread (\>5/week)   0.060    −0.132   0.625       0.201

BMI indicates body mass index; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.

The total score of the Mediterranean diet adherence questionnaire was associated to serum vitamin E levels and increased linearly with serum vitamin E (F=5.4; *P*=0.021). Among dietary elements analyzed by dietary questionnaire, olive oil consumption was the only component significantly associated to vitamin E level (*P*=0.04).

Primary Outcome
---------------

All patients were followed for a mean time of 22 months yielding a total of 1022 person‐years. Mean TTR was 64% of the time; conversely, INR values were below or above this range in 23% and 13% of the time, respectively.

Ninety‐two patients (16%) experienced a primary outcome (major or minor bleeding) during follow‐up: 73 minor and 19 major bleedings, of which 4 were cerebral hemorrhages ([Table 3](#tbl03){ref-type="table"}). No fatal bleedings were detected. The overall incidence rate of any bleeding event was 9.2/100 person‐years. Higher vitamin E serum levels were found in patients who experienced bleeding compared to those who did not (5.27±1.93 versus 4.48±1.97 μmol/mmol cholesterol; *P*\<0.001).

###### 

Bleeding Events

  ---------------------------- ----
  Minor Bleeding Events, n     73
  Epistaxis                    21
  Gastrointestinal             15
  Conjunctival                 14
  Hematuria                    14
  Oral                         2
  Cutaneous/postintervention   6
  Other                        1
  Major Bleeding Events, n     19
  Cerebral/subdural            4
  Articular                    3
  Gastrointestinal             3
  Muscular                     2
  Ocular                       2
  Epistaxis with fall in Hb    2
  Hematuria with fall in Hb    2
  Extended hematoma            1
  ---------------------------- ----

Clinical characteristics of patients with or without primary outcomes are summarized in [Table 4](#tbl04){ref-type="table"}. The only variables that significantly differed between the 2 groups were history of MI and cardiac revascularization, HAS‐BLED score, and vit E/chol serum levels.

###### 

Baseline Characteristics of Patients in Relation to Development of Primary Outcomes During the Follow‐up

  Characteristics               Patients Without Primary Outcomes, n=474   Patients With Primary Outcomes, n=92   *P* Value
  ----------------------------- ------------------------------------------ -------------------------------------- -----------
  Age, y                        73.3±8.5                                   73.7±6.4                               0.628
  Gender, males                 58                                         64                                     0.302
  BMI, kg/m^2^                  27.3±4.5                                   27.2±4.2                               0.877
  Arterial hypertension, %      89                                         82                                     0.069
  Diabetes, %                   21                                         17                                     0.421
  History of stroke/TIA, %      15                                         18                                     0.490
  History of MI/CHD, %          20                                         30                                     0.039
  Anti‐platelet therapy, %      15                                         17                                     0.754
  ACE‐inhibitors/ARBs, %        75                                         66                                     0.078
  Statins, %                    44                                         50                                     0.298
  β‐blockers, %                 38                                         45                                     0.182
  Ca‐antagonists, %             35                                         33                                     0.835
  TTR, %                        63.8±16.5                                  64.6±17.7                              0.684
  Length of OAT, months         33.7±21.9                                  36.5±21.9                              0.267
  CHADS~2~ score                2.0±1.2                                    1.84±1.2                               0.274
  HAS‐BLED score                1.4±0.8                                    1.7±0.8                                0.002
  Mediterranean dietary score   5.18±1.6                                   5.4±1.5                                0.266
  Vitamin E                     4.48±1.97                                  5.27±1.93                              \<0.001

BMI indicates body mass index; HAS‐BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (≥65 years), Drugs/alcohol concomitantly; MI, myocardial infarction; OAT, oral anticoagulant therapy; TIA, transient ischemic attack; TTR, therapeutic INR range.

Thus the NVAF population was categorized on the basis of the quartile values of vit E/chol observed in the overall population. During the follow‐up, 11 bleeding events occurred in the first vitamin E quartile (≤3.38 μmol/mmol cholesterol), 19 in the second quartile (≥3.39 and \<4.48 μmol/mmol cholesterol), 29 in the third (≥4.49 and \<5.55 μmol/mmol cholesterol), and 33 in the fourth (≥5.56 μmol/mmol cholesterol)**.**

Quartiles of vitamin E were analyzed by the Grambsch and Therneau test to assess the "proportional hazard" (PH) assumption. The assumption was not rejected with a (global) *P* value of 0.21. A significant increase of bleeding event rate across quartiles was observed (*P*=0.008; log‐rank test) ([Figure 1](#fig01){ref-type="fig"}).

![Kaplan--Meier estimates of time to main outcome events by vitamin E quartiles.](jah3-2-e000364-g1){#fig01}

The multivariable Cox proportional hazard model showed a significant linear trend by quartile (global *P*=0.0186) persisting after adjustment for HAS‐BLED score ([Table 5](#tbl05){ref-type="table"}).

###### 

Adjusted Hazard Ratios, Based on a Cox Proportional Hazards Model, of Bleeding Events

  Variable                                                              HR[\*](#tf5-1){ref-type="table-fn"}   *P* Value   CI 95%   
  --------------------------------------------------------------------- ------------------------------------- ----------- -------- -------
  Second vs first vitamin E quartile[\*](#tf5-2){ref-type="table-fn"}   1.739                                 0.145       0.826    3.661
  Third vs First vitamin E quartile[\*](#tf5-2){ref-type="table-fn"}    2.310                                 0.020       1.141    4.674
  Fourth vs First vitamin E quartile[\*](#tf5-2){ref-type="table-fn"}   2.689                                 0.005       1.351    5.351
  HAS‐BLED Score                                                        1.447                                 0.005       1.121    1.869
  History of MI/CHD                                                     1.404                                 0.163       0.87     2.26

CHD indicates coronary heart disease; CI indicates confidence interval; HAS‐BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (≥65 years), Drugs/alcohol concomitantly; HR, hazard ratio; MI, myocardial infarction.

Hazard ratio \>1.0 favors vascular events.

Global *P* value for vitamin E quartiles *P*=0.0186.

Since most of events were minor bleedings, we repeated a multivariable Cox proportional hazard model considering only minor bleedings as outcome. This subanalysis confirmed that HAS‐BLED (sHR 1.368 95% CI 1.040 to 1.799 *P*=0.025) and vitamin E quartiles (Thrid versus First quartile sHR 2.285 95% CI 1.048 to 4.984 *P*=0.038, Fourth versus First quartile sHR 2.316 95% CI 1.066 to 5.028 *P*=0.034) were predictors of minor bleedings.

Secondary Outcomes
------------------

MACEs were experienced by 34 patients (6%): 7 MIs, 3 fatal MIs, 9 ischemic strokes, 4 fatal ischemic strokes, 6 cardiac revascularizations, 5 vascular deaths (acute heart failure). The overall incidence rate of any MACE was 3.3/100 person‐years.

After dividing the population according to median value of vitamin E, a significantly lower rate of MACEs was observed in patients with higher levels of vitamin E (*P*=0.015; log‐rank test) ([Figure 2](#fig02){ref-type="fig"}).

![Kaplan--Meier estimates of time to secondary outcome events during the follow‐up according to median baseline value of vitamin E.](jah3-2-e000364-g2){#fig02}

Discussion
==========

The study provides the first evidence that in NVAF patients on OAT serum levels of vitamin E are predictors of bleedings, reinforcing the concept that vitamin E possesses anticoagulant properties.

Vitamin K antagonists are the most practiced and used agents available for preventing ischemic complications in patients affected by NVAF. Nevertheless OAT is burdened by bleeding complications and, in particular, by cerebral hemorrhage, which is the most feared and life‐threatening complication. In case of OAT, a correct initial evaluation of patients is, therefore, necessary to score for not only athero‐thrombotic risk, as assessed by the CHADS~2~ score, but also for bleeding risk, as assessed by the HAS‐BLED score. However, it is important to note that HAS‐BLED and CHADS~2~ scores share some common risk factors such as arterial hypertension, previous stroke, and age ≥65 years. This implies that some patients identified as at high risk for ischemic stroke may be also classified at high risk for bleeding, generating uncertainty for clinical decisions. Moreover, the "L" of HAS‐BLED score (labile "INR") is unusable with the new antithrombothic drugs (such as dabigatran, apixaban, and rivaroxaban), which actually do not need a continuous monitoring of INR values. Hence, new markers to identify patients who are prone to bleed are needed. In the present study we focused our attention on the possibility that vitamin E could represent a discriminant factor for bleeding in NVAF patients. The biologic plausibility of such a hypothesis stems from previous studies showing that vitamin E possesses both anticoagulant ^[@b18],[@b22],[@b39],[@b21]^ and antiplatelet properties.^[@b24],[@b40]--[@b41]^ In particular vitamin E interferes with vitamin K‐dependent activation of clotting factor and inhibits the expression of tissue factor, a glycoprotein which converts factor X to Xa^[@b20]--[@b22]^. Furthermore, a previous study from our group demonstrated that vitamin E inhibits platelet aggregation with an oxidative stress‐mediated mechanism.^[@b23]^

Thus, in our retrospective observational study, the overall incidence rate of any bleeding event was 9.2/100 person‐years. This rate is slightly higher than that previously reported (1.3% to 7.2% per year) in the setting of NVAF.^[@b2]^ Among 92 bleedings, 19 were major, of which 4 were cerebral/subdural hemorrhages (0.4% per year). This rate is similar to previously reported findings (0.1% to 2.5% per year).^[@b2]^

Herewith we provide the first evidence that vitamin E serum levels were associated with bleedings in patients with AF under VKA therapy. Of note, higher serum levels of vitamin E were able to predict major and minor bleedings independently from the HAS‐BLED scores. More in detail, a value of serum vitamin E ≥4.49 μmol/mmol cholesterol seemed to confer an increased risk for any bleeding, while levels ≥5.56 μmol/mmol cholesterol conferred the highest risk for major bleeding. In accordance with our study hypothesis, we found an inverse association between vitamin E serum levels and cardiovascular events persisting after adjustment for age, history of MI/coronary heart disease, history of stroke/TIA, and diabetes. This is in agreement with our recent report on this topic.^[@b9]^

Analysis of the determinants of vitamin E showed no relationship with classic risk factors or concomitant therapy. On the contrary, vitamin E serum levels linearly increased in patients at higher adherence to Mediterranean diet, suggesting that Mediterranean diet nutrients, which are rich in vitamin E, may affect serum levels.

Taken together these data lead us to hypothesize that the predictive value of vitamin E behaves as a U‐shaped curve with the lowest and highest values predicting ischemic and hemorrhagic events, respectively. The study has limitations and implications. The study may help to interpret data from a recent meta‐analysis showing that vitamin E supplementation reduced the risk of ischemic stroke by 10% but increased the risk for hemorrhagic stroke by 22%.^[@b42]^ Patients with vitamin E values \>5 μmol/mmol cholesterol should be warned for the use of any antioxidant treatment because they could be at a higher risk of bleeding.

A limitation of this study relates to the need of a specialized laboratory to measure vitamin E and in the lack of standardized references. In this regard, it should be underscored that vitamin E serum levels in our study refer to an Italian population living in the center‐south of the peninsula and cannot be extrapolated to other countries following a different diet. The clinical relevance of minor bleedings on the management of OAT patients has not yet been established. Therefore, considering minor bleedings as outcomes should be questionable. Finally, the study has been conducted in a single center only and should be confirmed by a multicenter study.

In conclusion, bleeding risk assessment still remains a crucial issue for patients affected by AF receiving OAT. Vitamin E serum levels could represent a useful tool for identifying NVAF patients at higher risk of bleeding. Further study is necessary to see if the relationship between serum levels of vitamin E and bleeding is still maintained with the use of new OAT.
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